InterMune will gain a $60 million up front fee from Roche on closing a deal to develop InterMune's experimental therapy for hepatitis C. Roche is also funding two thirds of the research costs of the HCV protease inhibitor ITMN-191. "Assuming the successful development and commercialization of ITMN-191 in the (United States) and other countries, InterMune could receive up to $470 million in milestones, including a potential $35 million within the next 12 months," the company said.
- read the UPI report on the deal